Skip to content

    Jubilant Pharmo

    JUBLPHARMAGood
    Healthcare·24 Feb 2025
    Management Summary

    Jubilant Pharmo delivered a strong performance update during its 2025 Investor Meet, highlighting a successful turnaround in its Generics and Radiopharmacy businesses. Management unveiled an ambitious 'Vision 2030' roadmap focusing on specialty pharmaceuticals and high-margin CDMO services. With 5 out of 6 facilities now VAI compliant and a clear path to zero net debt, the company is pivoting from a recovery phase to aggressive long-term growth.

    Highlights

    7

    • Vision 2030 target set to double revenue to ₹13,500 crores from ₹6,700 crores in FY24.

    • Trailing 12 Months (TTM) revenue as of Dec '24 reached ₹7,000 crores with an EBITDA margin of 16.3%.

    • Net Debt to EBITDA significantly reduced to 1.4x in Dec '24 from 2.9x in FY23.

    • Radiopharma segment remains the largest contributor, accounting for over 45% of total revenue.

    • Generics business achieved EBITDA break-even, a major turnaround from -30% margins two years ago.

    • CDMO Sterile Injectables capacity doubling in Spokane with a US $285 million expansion project.

    • Targeting zero net debt and high-teens ROCE by FY30.

    Concerns

    1

    • Montreal Facility OAI Classification

    What Changed1

    vs Q1 FY26

    Guidance items5 → 6 (+1)
    Key financials

    Metrics

    4

    Periods

    2

    Headline

    2
    • Net Debt to EBITDA
      1.4 x
      YoY-51.7%
    • Net Debt
      ₹2,500 Cr

    TTM

    2
    • Revenue
      ₹7,000 Cr
      YoY+12.9%
    • EBITDA Margin
      16.3%

    Segment breakdown

    Radiopharma
    45% Revenue Contribution7.5% Radiopharmacy EBITDA Margin
    Allergy Immunotherapy
    40% EBITDA Margin
    CDMO Sterile Injectables
    21% EBITDA Margin (TTM)
    Generics
    0% EBITDA Margin
    List

    Guidance & targets

    6
    CategoryTargetPriority
    Revenue
    Total Revenue
    ₹13,500 crores
    		High
    Margin
    EBITDA Margin
    23-25%
    		High
    Margin
    Generics EBITDA Margin
    15-17%
    		Medium
    Debt
    Net Debt
    Zero
    		High
    Other
    ROCE
    High Teens / 20%
    		Medium
    Capacity
    PET Pharmacies
    9
    		High

    Risks & concerns

    5
    RiskSeverity

    Montreal Facility OAI Classification

    The facility is currently under OAI; remediation is ongoing with a target for FDA re-inspection by end of FY26. — Both acknowledged

    high

    US-Canada Trade Tariffs

    Potential for short-term impact on Radiopharma supply chain; mitigation involves US-based inventory and tech transfers. — Analyst downplayed

    medium

    Biotech Funding Environment

    Management notes we are 'getting out of the winter season' but not yet in 'summer' regarding biotech funding levels. — Management acknowledged

    medium

    Areas of Evasion(2)

    • Specific revenue per pharmacy figures (cited as proprietary).
    • Detailed clinical trial data for MIBG before FDA sharing.

    Q&A highlights

    3

    “the plan is by the end of the fiscal year 26, we would invite the FDA back and ultimately remove the OAI classification.”

    Regulatory clearance of the Montreal facility is critical for de-risking the CDMO and Ophthalmic business.

    asked by Not identified

    2 min read5 chapters

    Detailed Narrative

    01

    Vision 2030: A Roadmap to ₹13,500 Crore Revenue

    Jubilant Pharmo has set an aggressive target to double its revenue to ₹13,500 crores by FY30, up from ₹6,700 crores in FY24. This growth is expected to be accompanied by significant margin expansion, with EBITDA targets moving from 15% to a range of 23-25%. The company plans to achieve this through a mix of specialty product launches in Radiopharma and doubling capacity in its CDMO Sterile Injectables business.

    02

    Radiopharma: Moving Up the Value Chain

    The Radiopharma segment, contributing over 45% of revenue, is pivoting towards PET imaging and advanced therapeutics. The company is investing US $50 million to expand its PET pharmacy network from 3 to 9 sites by FY28, targeting an ROCE of over 20%. Additionally, the MIBG therapeutic for Neuroblastoma is expected to file with the FDA in H2 FY25, with a peak sales potential of US $70-$100 million.

    03

    CDMO Sterile Injectables: Capacity and Technology Lead

    Management is doubling sterile injectable capacity at its Spokane facility, a US $285 million project partially funded by the US government. The new 'Line 3' will feature advanced isolator technology, which is increasingly demanded by big pharma for high-value biologics. Commercial revenues from this expansion are slated to begin by the end of 2026 (FY27), with segment EBITDA margins expected to exceed 25%.

    04

    Generics Turnaround and Future Growth

    The Generics business has successfully reached EBITDA break-even after being at -30% margins two years ago. With the Roorkee facility now VAI compliant, the company plans to launch 6-8 products annually in the US market. The long-term goal for this segment is to double the top line and achieve 15-17% EBITDA margins by FY30 through a combination of internal ANDA launches and in-licensing.

    05

    Strategic Acquisition in CRDMO

    Jubilant is acquiring an 80% stake in Pierre Fabre's facility in France to bolster its capabilities in Antibody-Drug Conjugates (ADC) and monoclonal antibodies. This acquisition provides a strategic foothold in Europe and aligns with the company's goal to triple CRDMO revenues by FY30. The company estimates a total CAPEX of US $150 million for this segment to sustain a 20% ROCE.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.